JEANNE HAGGERTY

Business and corporate tax issues, international tax reform; issues related to research and development.

Remote clinical trials, biomedical research & development.

Clinical trials and research.

Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.

Issues related to pharmaceutical manufacturing and development. Issues related to China WRT the BINSA bill.

Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP.

Issues related to pharmaceutical manufacturing and development. Issues related to China WRT the BINSA bill.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Issues related to patient access to home medical equipment and related reimbursement.

Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

Support for workforce training at community clinics.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices. CMS RAPID Proposed Rule.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Issues related to China WRT the BINSA bill.

H.R. 2145 - Recycling Infrastructure and Accessibility Act (RIAA).

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). Implementation of MCED, CMS RAPID proposed rule, and VA coverage of multi cancer tests.

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to most favored nation pricing polices.

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX. Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267).

International and domestic tax issues. Implementation of PL 119-21.

Strategic National Stockpile procurement issues.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing), access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Issues related to China WRT the BINSA bill.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. Issues related to China WRT the BINSA bill.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Issues related to TrumpRX.

General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research. Clinical Trial Modernization Act (HR 3521/S.4440).

Implementation of Medicare Multi-Cancer Early Detection Screening Coverage Act.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Issues related to China WRT the BINSA bill.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Issues related to TrumpRX.

Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.

Issues related to health insurance and affordability.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Engage on AI issues related to general AI, national security, drones, and waste, fraud and abuse.

Engage on AI issues related to general AI, national security, drones, and waste, fraud and abuse.

Engage on AI issues related to general AI, national security, drones, and waste, fraud and abuse.

Issues related to the prevention of the inclusion of illicit substances like tianeptine in dietary supplements. Mandatory Product Listing for dietary supplements. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision. General issues related to the dietary supplement industry. H.R. 7366 (Dietary Supplement Regulatory Uniformity Act).

Monitored the NDAA for any issues related to the dietary supplements industry.

Monitoring issues related to tariffs.

H.R. 1, One Big Beautiful Bill Act, issues related to R&D tax credit. Monitor trade and tariff issues related to pharmaceutical tariffs. Health care IP.

FDA drug approval, importation. Monitoring of changes to prescription drug advertising. PBM reform proposals, NIH funding, support and clinical trials.

H.R. 1, One Big Beautiful Bill Act implementation of ORPHAN CURES Act, Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act), IRA implementation of drug pricing provisions, Oppose proposed changes to the Medicaid Drug Rebate Program, Medicare coverage for anti-obesity medication and multi-cancer screening tests.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Issues related to pharmaceutical tariffs and related trade agreements.

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

Medicare Advantage, Medicaid coverage issues, IRA implementation.

Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars.

Issues related to patent protections.

Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.

Authorization of the NIH INCLUDE Initiative.

FY26 LHHS Funding for INCLUDE Initiative.

Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.

General education about estradiol patch supply and demand issues and discussions on FDA shortage evaluations.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.

Issues related to provisions in the annual appropriations process that regulate Hemp.

Issues related to regulation of Hemp products. H.R. 7024, Hemp Planting Predictability Act.

HR 7212 To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabinoid hemp products, and for other purposes. H.R.9830 - Lawful Hemp Protection Act.

Advocate on the regulatory environment regarding pediatric therapy services, including rulemakings at Health and Human Services.

Advocate on the regulatory environment regarding pediatric therapy services, including rulemakings at Health and Human Services.

Issues related to FDA approvals, and federal government policies related to stockpiling of essential medicines and the domestic or near-shoring of essential medicines.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Monitor selected health care legislation.

Engage on AI issues related to general AI, national security, drones, and waste, fraud and abuse.

Engage on AI issues related to general AI, national security, drones, and waste, fraud and abuse.

Engage on AI issues related to general AI, national security, drones, and waste, fraud and abuse.

Federal government relations and strategic advocacy to advance the company's U.S. policy objectives, including FDA regulatory matters and federal funding and contracting opportunities.

Federal government relations and strategic advocacy to advance the company's U.S. policy objectives, including FDA regulatory matters and federal funding and contracting opportunities.

Issues affecting the bottled water industry and water infrastructure.

Advocate on the regulatory environment regarding pediatric therapy services, including rulemakings at Health and Human Services.

Advocate on the regulatory environment regarding pediatric therapy services, including rulemakings at Health and Human Services.

Work to resolve supply shortage issues with female hormone patch.

General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals.

Animal health, issues impacting medicines and vaccines for animals.

Actions under Section 301 of the Trade Act of 1974, IEEPA, Section 232 of the Trade Expansion Act of 1962, and other trade-related authorities; export control actions and investment control proposals; other trade actions and developments.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.

Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Support for obesity drug coverage and access.

Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21.

Business and corporate tax issues, international tax reform; issues related to research and development.

Clinical trials and research.

Remote clinical trials, biomedical research & development.

Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.

Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

Issues related to pharmaceutical manufacturing and development.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

FY 2027 Appropriations.

Issues related to patient access to home medical equipment and related reimbursement.

Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

Support for workforce training at community clinics.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). HR 1, One Big Beautiful Bill Act.

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Issues related to pharmaceutical manufacturing and development.

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Strategic National Stockpile procurement issues.

Monitoring efforts to onshore and build US pharmaceutical manufacturing capacity.

Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research. Clinical Trial Modernization Act (HR 3521/S.4440).

Medicare Multi-Cancer Early Detection Screening Coverage Act.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Issues related to the prevention of the inclusion of illicit substances like tianeptine in dietary supplements. Mandatory Product Listing for dietary supplements. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision. General issues related to the dietary supplement industry.

Monitored the NDAA for any issues related to the dietary supplements industry.

Monitoring issues related to tariffs.

H.R. 1, One Big Beautiful Bill Act, issues related to R&D tax credit. Monitor trade and tariff issues related to pharmaceutical tariffs. Health care IP.

H.R. 1, One Big Beautiful Bill Act implementation of ORPHAN CURES Act, Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act), IRA implementation of drug pricing provisions, Oppose proposed changes to the Medicaid Drug Rebate Program, Medicare coverage for anti-obesity medication and multi-cancer screening tests.

FDA drug approval, importation. Monitoring of changes to prescription drug advertising. PBM reform proposals, NIH funding, support and clinical trials.

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Issues related to pharmaceutical tariffs and related trade agreements.

Medicare Advantage, Medicaid coverage issues, IRA implementation.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

Issues related to patent protections.

Issues related to antitrust legislation.

General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals.

HR 7212 To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabinoid hemp products, and for other purposes.

Issues related to provisions in the annual appropriations process that regulate Hemp.

Issues related to regulation of Hemp products. H.R. 7024, Hemp Planting Predictability Act.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to food and beverage regulation.

Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.

Issues related to health insurance and affordability.

FY26 LHHS Funding for INCLUDE Initiative.

Authorization of the NIH INCLUDE Initiative.

Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.

Monitor selected health care legislation.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Educate Congress and Administration officials on women's health issues, including prior authorization, the HEADACHE Act, access to care, and screening and prevention, and advise coalition members on legislative, regulations, and executive action.

Animal health, issues impacting medicines and vaccines for animals.

General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals.

Actions under Section 301 of the Trade Act of 1974, IEEPA, Section 232 of the Trade Expansion Act of 1962, and other trade-related authorities; export control actions and investment control proposals; other trade actions and developments.

Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21.

Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21.

Support for obesity drug coverage and access.

Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Business and corporate tax issues, international tax reform; including international minimum tax proposals; issues related to research and development.

Remote clinical trials, biomedical research & development.

Clinical trials and research.

Medicare coverage issue for non-opioid product. Reauthorization of NOPAIN Act.

Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

Issues related to pharmaceutical manufacturing and development.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

FY 2027 Appropriations.

Issues related to access to home medical equipment and related reimbursement (i.e., the "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4307) and the "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, the "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels. Issues related to continuous glucose monitors.

Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.

Support for workforce training at community clinics.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues.

Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.

Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.

Outreach on renewable energy project in Taoyuan City, Taiwan; U.S. International Development Finance Corporation which is not an option in the drop down box.

The Medicare Multi-Cancer Early Detection Screening Coverage Act. American Relief Act (P.L. 118-158). HR 1, One Big Beautiful Bill Act.

Issues related to pharmaceutical manufacturing and development.

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Drug importation, prescription drug safety, value and access.

Strategic National Stockpile procurement issues.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Monitoring efforts to onshore and build US pharmaceutical manufacturing capacity.

General cancer care access, innovation and screening, including childhood cancer; NIH funding for Cancer Research.

Medicare Multi-Cancer Early Detection Screening Coverage Act.

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Monitoring issues related to tariffs.

All legislative proposals related to the inclusion of dietary supplement purchases within tax-deductible Health Savings Accounts and Flexible Spending Accounts (HSAs/FSAs).

Issues related to the prevention of the inclusion of illicit substances like tianeptine in dietary supplements. Mandatory Product Listing for dietary supplements. Issues related to P.L. 103-417, the Dietary Supplement Health and Education Act of 1994 drug preclusion provision. General issues related to the dietary supplement industry.

H.R. 1, One Big Beautiful Bill Act, issues related to R&D tax credit. Monitor trade and tariff issues related to pharmaceutical tariffs. Health care IP.

FDA drug approval, importation. Monitoring of changes to prescription drug advertising. PBM reform proposals, NIH funding, support and clinical trials.

H.R. 1, One Big Beautiful Bill Act implementation of ORPHAN CURES Act, Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act), IRA implementation of drug pricing provisions, Oppose proposed changes to the Medicaid Drug Rebate Program, Medicare coverage for anti-obesity medication and multi-cancer screening tests.

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Issues related to pharmaceutical tariffs and related trade agreements.

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.

Medicare Advantage, Medicaid coverage issues, IRA implementation.

Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.

General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals.

Issues related to antitrust legislation.

Authorization of the NIH INCLUDE Initiative.

FY26 LHHS Funding for INCLUDE Initiative.